Previous close | 2.3700 |
Open | 2.3780 |
Bid | 2.2500 x 1000 |
Ask | 2.7000 x 900 |
Day's range | 2.3780 - 2.9000 |
52-week range | 1.8100 - 3.5700 |
Volume | |
Avg. volume | 10,522 |
Market cap | 232.825M |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8600 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.40 |
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I would like to welcome everyone to the Innate Pharma Full Year 2023 Financial […]
MARSEILLE, France, March 21, 2024--Innate Pharma reports Full Year 2023 financial results and business update
MARSEILLE, France, March 19, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations.